Back

Wild-type transthyretin amyloid cardiomyopathy: spironolactone as a therapeutic option?

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in pharmacology and pharmacotherapy (2) Aldosterone Antagonists Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Andre Martins

Leiria Hospital Centre, Leiria (Portugal)

6 More presentations in this session

Presentation thumbnail
Association between low-dose aspirin use and serum uric acid levels in older adults: a cross-sectional analysis from the baseline survey of the LAPIS study
Doctor X. Wang (Beijing, CN)
Abstract
Presentation thumbnail
Is there really a clinical benefit to using the new drugs for HFrEF in real life?
Mr V. Martinez Mateo (Alcazar de San Juan, ES)
Abstract
Presentation thumbnail
Impact of cardiac myosin inhibitor therapy on treatment of hypertension in hypertrophic obstructive cardiomyopathy
Doctor K. Paik (Winston Salem, US)
Abstract
Presentation thumbnail
Head-to-head randomized trials of atorvastatin and rosuvastatin: a systematic review and meta-analysis of changes in inflammatory biomarkers
Doctor A. Omayer (Dubai, AE)
Abstract
Presentation thumbnail
Let's talk about heart failure with preserved ejection fraction and mineralocorticosteroid receptor antagonists: real-world registry data
Doctor D. Besic (Zagreb, HR)
Abstract

Access the full session

Session thumbnail
ePosters in pharmacology and pharmacotherapy (2)

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Webinar
MRAs in heart failure: what's old is new again
thumbnail
Congress Presentation
Aldosterone-targeted therapies in hypertension
thumbnail
Congress Session
Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources